Rezolute (RZLT) Cash & Equivalents (2010 - 2026)
Rezolute recorded quarterly Cash & Equivalents of $11.2 million in Q1 2026, down 5.88% quarter-over-quarter from $11.9 million in Q4 2025, and down 23.29% year-over-year from $14.6 million in Q1 2025.
Rezolute's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $11.2 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 23.29% year-over-year to $11.2 million; the TTM figure through Mar 2026 stood at $11.2 million (down 23.29% YoY), while the FY2025 annual figure was $94.1 million, up 33.68% from the prior year.
- Cash & Equivalents came in at $11.2 million for Q1 2026 at Rezolute, down from $11.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $154.3 million in Q3 2022 to a low of $5.9 million in Q1 2024.
- A 5-year average of $48.3 million and a median of $14.6 million in 2025 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents sank 94.75% in 2023 and jumped 338.99% in 2024, its largest moves.
- Rezolute's Cash & Equivalents stood at $146.7 million in 2022, then tumbled by 91.48% to $12.5 million in 2023, then dropped by 28.82% to $8.9 million in 2024, then surged by 33.71% to $11.9 million in 2025, then decreased by 5.88% to $11.2 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $11.2 million, $11.9 million, and $9.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 11.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.20 Mn |
| Dec 31, 2025 | 11.90 Mn |
| Sep 30, 2025 | 9.10 Mn |
| Jun 30, 2025 | 94.11 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 8.90 Mn |
| Sep 30, 2024 | 10.47 Mn |
| Jun 30, 2024 | 70.40 Mn |
| Mar 31, 2024 | 5.90 Mn |
| Dec 31, 2023 | 12.50 Mn |
| Sep 30, 2023 | 8.10 Mn |
| Jun 30, 2023 | 16.04 Mn |
| Mar 31, 2023 | 33.74 Mn |
| Dec 31, 2022 | 146.75 Mn |
| Sep 30, 2022 | 154.32 Mn |
| Jun 30, 2022 | 150.41 Mn |
| Mar 31, 2022 | 63.42 Mn |
| Dec 31, 2021 | 77.40 Mn |
| Sep 30, 2021 | 37.30 Mn |
| Jun 30, 2021 | 41.05 Mn |
| Mar 31, 2021 | 31.99 Mn |
| Dec 31, 2020 | 37.60 Mn |
| Sep 30, 2020 | 6.40 Mn |
| Jun 30, 2020 | 77.40 Mn |
| Mar 31, 2020 | 14.03 Mn |
| Dec 31, 2019 | 18.18 Mn |
| Sep 30, 2019 | 22.10 Mn |
| Jun 30, 2019 | 37.60 Mn |
| Mar 31, 2019 | 15.34 Mn |
| Dec 31, 2018 | 258,000.00 |
| Sep 30, 2018 | 401,000.00 |
| Jun 30, 2018 | 1.65 Mn |
| Mar 31, 2012 | 6,943.00 |
| Dec 31, 2011 | 15,846.00 |
| Sep 30, 2011 | 23,478.00 |
| Jun 30, 2011 | 37,030.00 |
| Mar 31, 2011 | 40,554.00 |
| Dec 31, 2010 | 40,549.00 |
| Sep 30, 2010 | 3,000.00 |